EBM Analytics, Crows Nest, Sydney, New South Wales, Australia.
Joint Orthopaedic Centre, Sydney, New South Wales, Australia.
J Knee Surg. 2021 Jul;34(8):793-800. doi: 10.1055/s-0039-3400536. Epub 2019 Dec 30.
There are limited medium-term outcome data available for the Repicci II device in unicompartmental knee arthroplasty (UKA). The purpose of this study was to report the medium-term (minimum 2 years) patient-reported outcomes and long-term (up to 14 years) procedure survival in a consecutive series of patients undergoing an inlay prosthesis UKA (Repicci II) at an independent orthopaedic clinic. Patients presenting with medially localized unicompartmental knee osteoarthritis and meeting the criteria appropriate for UKA were recruited to a clinical patient registry at the time of presentation. A cemented unicompartmental prosthesis (Repicci II) was implanted using minimally invasive techniques with rapid postoperative mobilization. Patients were asked to complete patient-reported outcomes preoperatively and annually postoperatively. A procedure list was cross-matched with the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), and an analysis of procedure survival was performed with comparison to the national data for UKA. Data from a cohort of 661 primary medial compartment UKA procedures performed in 551 patients over a 15-year period were extracted from the clinical patient registry. Significant improvements were maintained in general health, disease symptoms, pain, and function at an average follow-up of 9 years compared with preoperative data. Threshold analysis revealed that >65% of patients exceeded Patient Acceptable Symptom State at the latest follow-up, with >80% within or exceeding age-matched norms for general health. Cumulative revision rate was significantly lower than that reported for UKA in the AOANJRR at up to 13 years follow-up. This series represents a lower cumulative revision rate than previously reported, with >65% of patients reporting satisfactory functional outcomes at an average of 9 years from surgery. Surgical options for treating unicompartmental knee osteoarthritis could include UKA as a viable alternative; however, clear definitions of procedure success and its overall cost-benefit ratio in the context of ongoing management of knee osteoarthritis remain to be elucidated.
Repicci II 装置在单间膝关节置换术中(UKA)的中期结果数据有限。本研究的目的是报告在一家独立骨科诊所连续系列接受嵌体假体 UKA(Repicci II)的患者的中期(至少 2 年)患者报告的结果和长期(最长 14 年)手术存活率。在出现时,符合 UKA 标准的有局限性单髁膝关节骨关节炎的患者被招募到临床患者登记处。使用微创技术植入骨水泥单髁假体(Repicci II),术后快速活动。患者被要求在术前和术后每年完成患者报告的结果。手术清单与澳大利亚骨科协会全国关节置换登记处(AOANJRR)交叉匹配,并与全国 UKA 数据进行比较分析手术存活率。从临床患者登记处提取了在 15 年内对 551 名患者进行的 661 例原发性内侧间室 UKA 手术的队列数据。与术前数据相比,在平均随访 9 年时,总体健康状况、疾病症状、疼痛和功能均保持显著改善。阈值分析显示,在最新随访时,>65%的患者超过了患者可接受的症状状态,>80%的患者在总体健康方面处于或超过了年龄匹配的正常值。累积翻修率在 13 年随访时明显低于 AOANJRR 报告的 UKA。与之前报告的结果相比,该系列的累积翻修率较低,>65%的患者在手术平均 9 年后报告了满意的功能结果。治疗单髁膝关节骨关节炎的手术选择可以包括 UKA 作为可行的替代方案;然而,在膝关节骨关节炎持续管理的背景下,手术成功的明确定义及其总体成本效益比仍有待阐明。